Articles by James Calloway
Boeing 737 MAX 7 and MAX 10 Near Final Regulatory Clearance
Boeing's 737 MAX 7 and MAX 10 are in the final stage of U.S. and European regulatory approval, with only documentation left. Certification is crucial for Boeing's cash recovery and airline customers.
FDA Greenlights uniQure's Accelerated Approval Path for Huntington's Gene Therapy
uniQure shares surged 78% premarket after the FDA agreed to accept three-year Phase I/II data as the basis for an accelerated approval filing for AMT-130 in Huntington's disease, reviving the near-term U.S. path for the potential first disease-modifying treatment.
CarMax Revenue Beat Fails to Ease Margin Concerns
CarMax beat Q1 revenue estimates at $8.01B, but retail gross profit per unit dropped to $2,177, highlighting ongoing margin pressure. Shares rose 5% premarket before settling near $52.11.
La-Z-Boy Surges on Q4 Earnings Beat, $300M Buyback
La-Z-Boy shares surged nearly 17% after hours after Q4 adjusted earnings of $1.26 per share beat estimates, offsetting a 7.2% drop in regular trading, as retail expansion and a $300 million buyback boosted sentiment.
Pfizer Shares Edge Up as Rigel Completes Veppanu Licensing Deal
Pfizer shares edged up after Rigel completed a Veppanu licensing deal with Arvinas, providing a $35 million payment to Pfizer.
AT&T Stock Hovers Near 52-Week Low Amid Debt and Dividend Concerns
AT&T shares fell 1.5% to $22.95, approaching a 52-week low, as the market weighs debt, capital spending, and competitive pressures ahead of Q2 earnings on July 22.
Ford Stock Dips on China Software Rule Uncertainty
Ford shares slipped 1.1% to $14.61 after Reuters reported the company needs U.S. approval to keep importing China-built Lincoln Nautilus SUVs due to new connected-vehicle rules.
Moderna Shares Surge on Positive FDA Staff Review for mRNA Flu Vaccine
Moderna shares surged nearly 10% to $57.19 after FDA staff said data on its mRNA flu shot may support effectiveness in adults 65+, lowering regulatory risk ahead of a key advisory panel vote.
Groupe Dynamite Shares Tumble Despite Strong Q1 Revenue Growth
Groupe Dynamite shares plunged 33% to CA$49.83 despite Q1 revenue surging 37% and adjusted EPS doubling, as investors reacted to cautious 2026 guidance, lower free cash flow, and trimmed store opening plans.
Micron Shares Slip After Record High as Investors Eye AI Earnings Test
Micron shares slipped 3.6% to $1,048.87 after a record close, as profit-taking emerged ahead of the June 24 earnings report that will test AI memory demand and the stock's lofty valuation.
Netflix Declines on M&A Worries Ahead of Q2 Earnings
Netflix shares fell 2.7% amid M&A chatter, as investors worry deal risk could divert cash from buybacks or content. The July 16 earnings report is the next key catalyst.